A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

Todd A. Fehniger; Marcus P. Watkins; Nkiruka Ezenwajiaku; Fei Wan; David D. Hurd; Amanda F. Cashen; Kristie A. Blum; Andre Goy; Timothy S. Fenske; Nina D. Wagner-Johnston; Kenneth Carson; Marilyn J. Siegel; David Russler-Germain; Stephanie E. Schneider; Neha Mehta-Shah; Brad Kahl; Nancy L. Bartlett

doi:10.3324/haematol.2022.282246

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

Todd A. Fehniger, Marcus P. Watkins, Nkiruka Ezenwajiaku, Fei Wan, David D. Hurd, Amanda F. Cashen, Kristie A. Blum, Andre Goy, Timothy S. Fenske, Nina D. Wagner-Johnston, Kenneth Carson, Marilyn J. Siegel, David Russler-Germain, Stephanie E. Schneider, Neha Mehta-Shah, Brad Kahl, Nancy L. Bartlett

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	953-957
Number of pages	5
Journal	Haematologica
Volume	109
Issue number	3
DOIs	https://doi.org/10.3324/haematol.2022.282246
State	Published - Mar 2024

Access to Document

10.3324/haematol.2022.282246

Cite this

Fehniger, T. A., Watkins, M. P., Ezenwajiaku, N., Wan, F., Hurd, D. D., Cashen, A. F., Blum, K. A., Goy, A., Fenske, T. S., Wagner-Johnston, N. D., Carson, K., Siegel, M. J., Russler-Germain, D., Schneider, S. E., Mehta-Shah, N., Kahl, B., & Bartlett, N. L. (2024). A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma. Haematologica, 109(3), 953-957. https://doi.org/10.3324/haematol.2022.282246

@article{490d4606939d41cd9c722ad4b361dce6,

title = "A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma",

author = "Fehniger, {Todd A.} and Watkins, {Marcus P.} and Nkiruka Ezenwajiaku and Fei Wan and Hurd, {David D.} and Cashen, {Amanda F.} and Blum, {Kristie A.} and Andre Goy and Fenske, {Timothy S.} and Wagner-Johnston, {Nina D.} and Kenneth Carson and Siegel, {Marilyn J.} and David Russler-Germain and Schneider, {Stephanie E.} and Neha Mehta-Shah and Brad Kahl and Bartlett, {Nancy L.}",

year = "2024",

month = mar,

doi = "10.3324/haematol.2022.282246",

language = "English",

volume = "109",

pages = "953--957",

journal = "Haematologica",

issn = "0390-6078",

number = "3",

}

Fehniger, TA, Watkins, MP, Ezenwajiaku, N, Wan, F, Hurd, DD, Cashen, AF, Blum, KA, Goy, A, Fenske, TS, Wagner-Johnston, ND, Carson, K, Siegel, MJ , Russler-Germain, D, Schneider, SE, Mehta-Shah, N , Kahl, B & Bartlett, NL 2024, 'A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma', Haematologica, vol. 109, no. 3, pp. 953-957. https://doi.org/10.3324/haematol.2022.282246

TY - JOUR

T1 - A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

AU - Fehniger, Todd A.

AU - Watkins, Marcus P.

AU - Ezenwajiaku, Nkiruka

AU - Wan, Fei

AU - Hurd, David D.

AU - Cashen, Amanda F.

AU - Blum, Kristie A.

AU - Goy, Andre

AU - Fenske, Timothy S.

AU - Wagner-Johnston, Nina D.

AU - Carson, Kenneth

AU - Siegel, Marilyn J.

AU - Russler-Germain, David

AU - Schneider, Stephanie E.

AU - Mehta-Shah, Neha

AU - Kahl, Brad

AU - Bartlett, Nancy L.

PY - 2024/3

Y1 - 2024/3

UR - http://www.scopus.com/inward/record.url?scp=85186747096&partnerID=8YFLogxK

U2 - 10.3324/haematol.2022.282246

DO - 10.3324/haematol.2022.282246

M3 - Letter

C2 - 37706336

AN - SCOPUS:85186747096

SN - 0390-6078

VL - 109

SP - 953

EP - 957

JO - Haematologica

JF - Haematologica

IS - 3

ER -

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

Access to Document

Other files and links

Cite this